OSI, Genentech Slump on Avastin-Tarceva Miss

OSI, Genentech Slump on Avastin-Tarceva Miss. BIOWORLD Today - Oct. 10, 2008 Byline: Donna Young, Washington Editor Shares of Genentech Inc. and OSI Pharmaceuticals Inc. took a beating Monday on the news that their targeted therapies Avastin (bevacizumab) and Tarceva (erlotinib) in combination failed in a Phase III trial to improve overall survival of patients with non-small-cell lung cancer... [read full story]                    

Add Comment
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies